Evidence map›Paper›PMID 26155388›Full record

ReviewOncoimmunology2015

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Pierre Combe, Eleonore de Guillebon, Constance Thibault, Clémence Granier, Eric Tartour, Stéphane Oudard

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Immunotherapy for metastatic renal cell carcinoma.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Novel immunotherapy in metastatic renal cell carcinoma.Investigative and clinical urology · 2017
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Pierre CombeDepartment of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France ; INSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France.
Eleonore de GuillebonDepartment of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France ; INSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France.
Constance ThibaultDepartment of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France.
Clémence GranierINSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France ; Department of Biological Immunology; Hôpital Européen Georges-Pompidou (AP-HP) ; Paris, France.
Eric TartourINSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France ; Department of Biological Immunology; Hôpital Européen Georges-Pompidou (AP-HP) ; Paris, France.
Stéphane OudardDepartment of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France ; INSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France.
Université Paris Cité · FRHôpital Européen · FRHôpital Européen Georges-Pompidou · FRParis Cardiovascular Research Center · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the renaissance of cancer immunotherapy, no novel immunotherapy has been approved for the treatment of renal cell cancer (RCC) since the availability of recombinant cytokines (interleukin-2, interferon-α). All vaccine trials have failed to meet their endpoints although they have highlighted potential predictive biomarkers (e.g., pre-existing immune response, hematological parameters, tumor burden). Recent advances in immunomodulatory therapies have prompted the study of combination treatments targeting the tumor immunosuppressive microenvironment consisting of regulatory T-cells (Treg), myeloid suppressor cells, and cytokines. Approaches under investigation are use of inhibitors to curb the overexpression of immune checkpoint ligands by tumor cells (e.g., anti-CTLA-4, anti-PD-1/PD-L1) and exploiting the immunomodulatory effects of anti-angiogenic agents that are the current standard of metastatic RCC care. Phase III trials are focusing on the possible synergy between therapeutic vaccines (e.g., IMA-901 and AGS-003) and anti-angiogenic agents.

Indexed as

AGS-003anti-angiogenic agentCAIXcarbonic anhydrase IX; ccRCCcheckpoint inhibitorclear cell renal cell carcinoma; CIKcytokine induced killer; CTLcytotoxic T-lymphocyte-associated protein 4; DCcytotoxic T-lymphocyte; CTLA-4dendritic cell; GM-CSFgranulocyte macrophage colony-stimulating factor; HGFheat shock protein; IFNhepatocyte growth factor; HLAhuman leukocyte antigen; HSPIMA-901interferon; ILinterleukin; KIRkiller immunoglobin-like receptor; MDRmajor histocompatibility complex; MSKCCMemorial Sloan Kettering Cancer Center; NKmultidrug resistance protein; MDSCmyeloid derived suppressor cell; MHCnatural killer; ORRoverall response rate; OSperipheral blood mononuclear cell; PD-1phosphatase and tensin homolog; TAAprogrammed cell death ligand 1; PTENprogrammed cell death protein 1; PD-L1regulatory T-cell; TUMAPrenal cell carcinomatherapeutic vaccinetoll-like receptor; Tregtumor-associated antigen; TILtumor-associated peptide; VEGFtumor infiltrating lymphocyte; TLRvascular endothelial growth factor; VHLverall survival; PBMCVon Hippel Landau

Identifiers

PMID26155388
PMCPMC4485845
OpenAlexW1529568247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.